Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new lens design keep Kids' eyesight sharp?

NCT ID NCT07779941

Prevention Sponsor: Singapore National Eye Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This study tests whether ZEISS MyoActive lenses, designed to send a specific optical signal to the eye, can prevent or delay the onset of short-sightedness (myopia) in children who are not yet myopic but are at risk. Children aged 6 to 12 with mild farsightedness will be randomly assigned to wear either these special lenses or standard single-vision glasses for 12 months. Researchers will track changes in their eye measurements and vision to see if the lenses slow eye growth and reduce the chance of becoming myopic.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ZEISS MyoActive spectacle lenses
What this could lead to
If effective, these lenses could offer a simple, non-invasive way to prevent or delay myopia onset in children, reducing future risks of high myopia and related eye conditions.
What could go wrong
This is a small pilot study, so results may not be conclusive. The lenses may not prevent myopia, and there could be unknown side effects or discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 124 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 12 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Participants enrolled in the trial must: 1. be accompanied by a parent or guardian who is able to read and comprehend English and sign a record of informed consent/assent; 2. be able to understand and participate in the Assent process; 3. at baseline, be within the age range of 6 to 12 years old inclusive; 4. No prior spectacle correction 5. Cycloplegic spherical equivalent (SE) 0.00 to + 2.00 D 6. Astigmatism of less than -1.50D 7. Anisometropia of not more than 1.50D 8. At least 1 parent or more with myopia Exclusion Criteria Participants enrolled in the trial must NOT have: * Any pre-existing systemic or ocular condition, including infection or disease that is likely to affect visual acuity and refractive error; * Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. * Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology in an adverse or beneficial manner at enrolment and/or during the study. NB: Systemic antihistamines are allowed on an "as needed basis", provided they are not used prophylactically during the trial and at least 24 hours before the study product is used. * History of eye trauma * Amblyopia * Strabismus * History of any form of optical correction * Any concomitant myopia control treatment including atropine eyedrops, contact lenses or other myopia control glasses. The Investigator may, at their discretion, exclude anyone who they believe may not be able to fulfil the study requirements or it is believed to be in the participant's best interests.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myopia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia Pre-myopia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Singapore National Eye Centre

    Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.